Curis Inc (CRIS)

NASDAQ
7.660
-0.110(-1.42%)
After Hours
7.620
-0.040(-0.522%)
- Real-time Data
  • Volume:
    869,269
  • Bid/Ask:
    7.600/7.620
  • Day's Range:
    7.645 - 7.940

CRIS Overview

Prev. Close
7.77
Day's Range
7.645-7.94
Revenue
10.31M
Open
7.76
52 wk Range
0.9-17.2
EPS
-0.5
Volume
869,269
Market Cap
701.16M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,794,865
P/E Ratio
-
Beta
2.92
1-Year Change
522.76%
Shares Outstanding
91,535,272
Next Earnings Date
02 Aug 2021
What is your sentiment on Curis Inc?
or
Market is currently closed. Voting is open during market hours.

Curis Inc News

Curis Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralSellNeutral
Technical IndicatorsStrong SellStrong SellBuyStrong BuyBuy
SummaryStrong SellStrong SellNeutralNeutralNeutral

Curis Inc Company Profile

Curis Inc Company Profile

Employees
28

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Read More
  • curis share prices fall down this is pump dump scam
    0
    • this is a rising stock
      0
      • Curis share prices fall down this is a pump and dump scam
        0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.